QuikChange Site-Directed Mutagenesis Kit, 10 Rxn

Site Directed Mutagenesis (SDM) Human - Point mutation 786-O SIRT1

Experiment
Site Directed Mutagenesis (SDM) Human - Point mutation 786-O SIRT1
Product
QuikChange Site-Directed Mutagenesis Kit, 10 Rxn from Agilent Technologies
Manufacturer
Agilent Technologies

Protocol tips

Upstream tips
- XL10-Gold cells are resistant to tetracycline and chloramphenicol. If the mutagenized plasmid contains only the tetR or camR resistance marker, an alternative strain of competent cells must be used.
Protocol tips
- Use only the Dpn I enzyme provided; do not substitute with an enzyme from another source.

Publication protocol

Vector construction and luciferase reporter assay
A human SIRT1 3′UTR was amplified from renal cancer cell line cDNAs and cloned into the XhoI/NotI site of a psiCHECK-2 vector (Promega, Madison, WI, USA). For mutagenesis of the miR-22-binding site, a QuikChange Site-Directed Mutagenesis kit (Agilent Technologies, Palo Alto, CA, USA) was used following the manufacturer's instructions.

For luciferase activity assay, 786-O cells were seeded into 12-well plates overnight before transfection, and then co-transfected with 200 ng of psiCHECK-2 vectors, which harbored SIRT1 3′UTR wild-type or mutant constructs, and 200 nM of miR-22 or miR-NC. Forty-eight hours after transfection, luciferase activity was measured with a Dual-Luciferase assay kit (Promega) according to the manufacturer's instructions. Renilla luciferase activity was normalized to firefly luciferase activity.

Full paper   Login or join for free to view the full paper.

Reviews

QuikChange Site-Directed Mutagenesis Kit, 10 Rxn from Agilent Technologies has not yet been reviewed for this experiment

We'd love it if you would be the first to write a review!

Discussion

Start your discussion

Share your thoughts or question with experts in your field

Start a discussion

Papers

Check out relevant papers found by Labettor's AI that are relevant for performing Site Directed Mutagenesis (SDM) Human - Point mutation 786-O SIRT1 using QuikChange Site-Directed Mutagenesis Kit, 10 Rxn from Agilent Technologies.

Paper title
MicroRNA-22 functions as a tumor suppressor by targeting SIRT1 in renal cell carcinoma.
Full paper
Login or join for free to view the full paper.

Manufacturer protocol

Download the product protocol from Agilent Technologies for QuikChange Site-Directed Mutagenesis Kit, 10 Rxn below.

Download PDF Download manufacturer protocol

Videos

Check out videos that might be relevant for performing Site Directed Mutagenesis (SDM) Human - Point mutation 786-O SIRT1 using QuikChange Site-Directed Mutagenesis Kit, 10 Rxn from Agilent Technologies. Please note that these videos are representative and steps or experiment specific processes must be kept in mind to expect desired results.

We haven't found any additional videos for this experiment / product combination yet.

Outsource your experiment

Fill out your contact details and receive price quotes in your Inbox

  Outsource experiment
Become shareholder Discussions About us Contact Privacy Terms